cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Veracyte Inc
3 own
5 watching
Current Price
$25.81
$-0.11
(-0.42%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,868.21M
52-Week High
52-Week High
32.4
52-Week Low
52-Week Low
14.92
Average Volume
Average Volume
0.63M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,868.21M
icon52-Week High32.4
icon52-Week Low14.92
iconAverage Volume0.63M
iconDividend Yield--
iconP/E Ratio--
What does the Veracyte Inc do?
Veracyte, Inc. operates as a molecular diagnostics company in the United States. The company uses genomic technology to resolve diagnostic ambiguity. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company's products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. It sells its products through its product specialists, institutional channel managers, account managers, and clinical science specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Read More
How much money does Veracyte Inc make?
News & Events about Veracyte Inc.
Business Wire
1month ago
Veracyte, Inc. (Nasdaq: VCYT) announced findings from a large-scale, systematic literature review showing that TERT promoter gene mutations in thyroid nodules deemed indeterminate by cytopathology are rare, but have a high risk of malignancy and, in certain cases, are associated with aggressive...
Business Wire
1month ago
Veracyte, Inc. (Nasdaq: VCYT) today announced that it released its inaugural Environmental, Social and Governance (ESG) Report. The 2023 ESG Report sets the foundation for Veracytes ESG performance and outlines the companys ambitions to build upon its progress in the years ahead. As our company has...
Business Wire
1month ago
Veracyte, Inc. (Nasdaq: VCYT) announced that new data published in European Urology Oncology suggest the Decipher Prostate Genomic Classifier could help identify prostate cancer patients who have micrometastatic disease (difficult-to-detect tumor cells that extend beyond the prostate) and who may...
Business Wire
1month ago
Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts highlighting new data from studies of the companys Decipher urologic cancer tests will be presented at the American Urological Association (AUA) Annual Meeting, taking place April 28-May 1, 2023, at McCormick Place in Chicago. The...
Business Wire
2 months ago
Veracyte, Inc. (Nasdaq: VCYT) outlined the companys cash, cash equivalents and short-term investment status in light of the events surrounding Silicon Valley Bank (SVB). As of December 31, 2022, the company had $178.9 million in cash, cash equivalents and short-term investments. The majority of...
Frequently Asked Questions
Frequently Asked Questions
What is Veracyte Inc share price today?
plus_minus_icon
Can Indians buy Veracyte Inc shares?
plus_minus_icon
How can I buy Veracyte Inc shares from India?
plus_minus_icon
Can Fractional shares of Veracyte Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Veracyte Inc stocks?
plus_minus_icon
What is today’s traded volume of Veracyte Inc?
plus_minus_icon
What is today’s market capitalisation of Veracyte Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Veracyte Inc?
plus_minus_icon
What percentage is Veracyte Inc down from its 52-Week High?
plus_minus_icon
What percentage is Veracyte Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$25.81
$-0.11
(-0.42%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
National HealthCare Corporation
National HealthCare Corporation
$62.49
$1.09 (1.78 %)
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$26.82
$0.76 (2.92 %)
MacroGenics, Inc.
MacroGenics, Inc.
$5.19
$0.17 (3.39 %)
Addus HomeCare Corp
Addus HomeCare Corp
$93.84
$0.41 (0.44 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
National HealthCare Corporation
National HealthCare Corporation
$62.49
$1.09 (1.78 %)
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$26.82
$0.76 (2.92 %)
MacroGenics, Inc.
MacroGenics, Inc.
$5.19
$0.17 (3.39 %)
Addus HomeCare Corp
Addus HomeCare Corp
$93.84
$0.41 (0.44 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00